Ciprofloxacin + Hydrocortisone Ear Drops Suppliers & Bulk Manufacturers
Available Forms: Ear drops
Available Strengths: 0.2 % Cpro + 0.1 % HC
Reference Brands: Cipro HC Otic(US)
Category:
ENT
Ciprofloxacin + hydrocortisone ear drops combine an antibiotic that inhibits bacterial DNA replication with a corticosteroid that reduces inflammation. They effectively treat bacterial ear infections, decrease pain, swelling, and redness, and prevent complications. Benefits include rapid infection control, symptom relief, and reduced inflammation under medical supervision worldwide.
Ciprofloxacin + Hydrocortisone ear drops is available in Ear drops
and strengths such as 0.2 % Cpro + 0.1 % HC.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ciprofloxacin + Hydrocortisone ear drops is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ciprofloxacin + Hydrocortisone ear drops can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ciprofloxacin + hydrocortisone ear drops, marketed as Cipro HC Otic, are approved in the US by the FDA and in the EU via EMA for bacterial ear infections with inflammation. Regulatory approval requires dossiers including safety, efficacy, manufacturing standards, and pharmacovigilance plans. The FDA reviews clinical and quality data for timely approval, while the EMA ensures regional safety and manufacturing compliance. For dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports swift approval, safe use, and worldwide availability, enabling effective treatment of bacterial otitis media and externa, reducing symptoms, and preventing complications across healthcare regions globally.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing